Drugs / DWC20155
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT03005223 | Jan → May 2017 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT02952755 | Nov → Dec 2016 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT02952547 | Oct → Nov 2016 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT02947139 | Sep → Oct 2016 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 1 | NCT03016494 | Feb 2016 → Mar 2017 | — | Daewoong Pharmaceutical Co. LTD. | Unknown | No outcome recorded |
| Phase 1 | NCT02704559 | Dec 2015 → Feb 2016 | — | Daewoong Pharmaceutical Co. LTD. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03184415 | Jul 2017 → May 2018 | gastritis | Daewoong Pharmaceutical Co. LTD. | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DWC20155 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02952755 ↗ |
| Route | Oral | “oral dose” NCT02704559 ↗ |